- Corydaline
-
- $0.00 / 1KG
-
2025-05-23
- CAS:518-69-4
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 500000kg
- Corydaline
-
- $0.00 / 25KG
-
2025-05-16
- CAS:518-69-4
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 50000KG/month
- Corydaline
-
- $55.00 / 5mg
-
2025-04-30
- CAS:518-69-4
- Min. Order:
- Purity: 99.86%
- Supply Ability: 10g
|
| | Corydaline Basic information |
| Product Name: | Corydaline | | Synonyms: | [7S,13S,13aR,(+)]-5,8,13,13a-Tetrahydro-2,3,9,10-tetramethoxy-13-methyl-6H-dibenzo[a,g]quinolizine;2,3,9,10-TetraMethoxy-13-Methylberbine, 8CI;(13s-e)-thyl;2,3,9,10-tetramethoxy-13-alpha-methyl-13a-beta-berbin;2,3,9,10-tetramethoxy-13-methyl-berbin;6h-dibenzo(a,g)quinolizine,5,8,13,13a-tetrahydro-2,3,9,10-tetramethoxy-13-me;Corydaline std.;(+) CORYDALINE | | CAS: | 518-69-4 | | MF: | C22H27NO4 | | MW: | 369.45 | | EINECS: | | | Product Categories: | Alkaloids;standardized herbal extract;reference standards from Chinese medicinal herbs (TCM).;phytochemical;pharmaceutical intermediate;chemical reagent | | Mol File: | 518-69-4.mol |  |
| | Corydaline Chemical Properties |
| Melting point | 135° | | alpha | D20 +311° (c = 0.8 in alc) | | Boiling point | 499.57°C (rough estimate) | | density | 1.1771 (rough estimate) | | refractive index | 1.5614 (estimate) | | storage temp. | 2-8°C(protect from light) | | solubility | Chloroform (Slightly), Methanol (Slightly, Sonicated) | | form | Solid | | pka | 6.57±0.40(Predicted) | | color | White to Off-White | | InChIKey | VRSRXLJTYQVOHC-YEJXKQKISA-N |
| HS Code | 2939799090 | | Toxicity | LD50 in mice (mg/kg): 135.5 ± 12.8 i.v. (Anderson, Chen) |
| | Corydaline Usage And Synthesis |
| Uses | Corydaline is a common herbal drug used in Chinese medicine and is touted as an analgesic with reported anti-angiogenic effects. | | Definition | ChEBI: Corydaline is an isoquinoline alkaloid and a member of isoquinolines. | | in vivo | Corydaline (10 mg/kg; subcutaneous administration; once) treatment shows antinociceptive effects in mice by significantly inhibiting the writhing behavior[3]. | Animal Model: | Male CD1 mice (30-35 g, 7-8 weeks old) injected with acetic acid[3] | | Dosage: | 10 mg/kg | | Administration: | Subcutaneous administration; once | | Result: | Showed antinociceptive effects in mice. |
| | IC 50 | AChE; μ Opioid Receptor/MOR |
| | Corydaline Preparation Products And Raw materials |
|